Assembly Biosciences Shares Soar Premarket on Gilead Pact
By Colin Kellaher
Shares of Assembly Biosciences more than doubled in premarket trading Tuesday after the biotechnology company inked a collaboration deal potentially worth hundreds of millions of dollars with Gilead Sciences.
As part of the 12-year agreement, Assembly is receiving an upfront payment of $100 million from Gilead, including $85 million in cash and a $15 million equity investment at $1.16 a share, a 60% premium to Monday's closing price of 72.6 cents.
The initial purchase gives Gilead a 19.9% stake in Assembly, which had a market capitalization of about $37.4 million based on Monday's closing price.
Assembly shares were recently up 130% to $1.67 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 17, 2023 08:29 ET (12:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits